BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci
- PMID: 15572191
- DOI: 10.1016/j.peptides.2004.08.005
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci
Abstract
Staphylococci are a major cause of infections associated with indwelling medical devices. Biofilm formation on these devices adds to the antibiotic resistance seen among clinical isolates. RNAIII-inhibiting peptide (RIP) is a heptapeptide that inhibits staphylococcal pathogenesis, including biofilm formation, by obstructing quorum sensing mechanisms. Bismuth ethanedithiol (BisEDT) also prevents biofilm formation at subinhibitory concentrations. RIP and BisEDT were combined to prevent infections in a rat graft model, using antibiotic sensitive and resistant strains of Staphylococcus aureus and Staphylococcus epidermidis. BisEDT, RIP, or rifampin, or their combinations reduced the graft associated bacterial load over seven days. BisEDT-RIP was the best combination, reducing bacterial load to undetectable levels. BisEDT-RIP may prove useful for coating medical devices to prevent staphylococcal infections.
Similar articles
-
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.J Infect Dis. 2004 Jul 15;190(2):318-20. doi: 10.1086/386546. Epub 2004 Jun 24. J Infect Dis. 2004. PMID: 15216467
-
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.Circulation. 2003 Aug 12;108(6):767-71. doi: 10.1161/01.CIR.0000083717.85060.16. Epub 2003 Jul 28. Circulation. 2003. PMID: 12885754
-
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis.J Infect Dis. 2003 Feb 15;187(4):625-30. doi: 10.1086/345879. Epub 2003 Feb 7. J Infect Dis. 2003. PMID: 12599079
-
Staphylococcus epidermidis device-related infections: pathogenesis and clinical management.J Pharm Pharmacol. 2008 Dec;60(12):1551-71. doi: 10.1211/jpp/60.12.0001. J Pharm Pharmacol. 2008. PMID: 19000360 Review.
-
Quorum-sensing control in Staphylococci -- a target for antimicrobial drug therapy?FEMS Microbiol Lett. 2004 Dec 15;241(2):135-41. doi: 10.1016/j.femsle.2004.11.016. FEMS Microbiol Lett. 2004. PMID: 15598524 Review.
Cited by
-
Inactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureus.Infect Immun. 2007 Sep;75(9):4519-27. doi: 10.1128/IAI.00491-07. Epub 2007 Jun 4. Infect Immun. 2007. PMID: 17548478 Free PMC article.
-
Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence.Infect Immun. 2005 Oct;73(10):6220-8. doi: 10.1128/IAI.73.10.6220-6228.2005. Infect Immun. 2005. PMID: 16177293 Free PMC article.
-
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.Antimicrob Agents Chemother. 2007 Jun;51(6):2226-9. doi: 10.1128/AAC.01097-06. Epub 2007 Mar 19. Antimicrob Agents Chemother. 2007. PMID: 17371825 Free PMC article.
-
Bench-to-bedside review: Quorum sensing and the role of cell-to-cell communication during invasive bacterial infection.Crit Care. 2008;12(6):236. doi: 10.1186/cc7101. Epub 2008 Nov 25. Crit Care. 2008. PMID: 19040778 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous